Given the clinical context of these mutations in breast cancer, these mutations are of potential clinical benefit to the patient that may have implications for PIK3CA inhibitors that target the PI3K/AKT/mTOR pathway[21,22]. This evidence concerns the gene AKT1 and breast carcinoma.